Ascletis Pharma
Hangzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A commercial biotech with a marketed HCV therapy and a pipeline in viral diseases and oncology.
Infectious DiseaseOncologyMetabolic
Technology Platform
Multiple platforms including small molecule protease inhibitor R&D for viral/metabolic diseases and a biologics platform for oncology immunotherapy.
Opportunities
Potential blockbuster opportunity in NASH if its lead candidate succeeds in late-stage trials for a disease with no approved pharmacotherapy.
Risk Factors
Clinical failure in its high-stakes NASH program would significantly impact valuation and long-term growth prospects.
Competitive Landscape
Faces competition in HCV from generics, in NASH from large pharma, and in oncology from many well-funded biotechs.